Literature DB >> 26126905

The Role of Binding Kinetics in GPCR Drug Discovery.

David C Swinney, Brad A Haubrich, Isabelle Van Liefde, Georges Vauquelin1.   

Abstract

Binding kinetics are the rates of association and dissociation of a drug-protein complex and are important molecular descriptors for the optimization of drug binding to G-protein coupled receptors (GPCRs). There are now many examples of binding kinetics in GPCR drug discovery. In this report, the first principles and examples of binding kinetics in GPCR drug discovery are reviewed. Addressed are the influence of binding kinetics on the translation of binding to the therapeutic window in the context of the equilibrium state of the system and molecular mechanisms of slow binding including induced fit, displacement of water, rebinding and heterovalency.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26126905     DOI: 10.2174/1568026615666150701113054

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  15 in total

1.  Does the Lipid Bilayer Orchestrate Access and Binding of Ligands to Transmembrane Orthosteric/Allosteric Sites of G Protein-Coupled Receptors?

Authors:  Christopher T Szlenk; Jeevan B Gc; Senthil Natesan
Journal:  Mol Pharmacol       Date:  2019-04-08       Impact factor: 4.436

2.  Effects of target binding kinetics on in vivo drug efficacy: koff , kon and rebinding.

Authors:  Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2016-07-04       Impact factor: 8.739

Review 3.  Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo.

Authors:  Georges Vauquelin
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

4.  Distinct in vivo target occupancy by bivalent- and induced-fit-like binding drugs.

Authors:  Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2017-10-18       Impact factor: 8.739

Review 5.  Fluorescent ligands: Bringing light to emerging GPCR paradigms.

Authors:  Mark Soave; Stephen J Briddon; Stephen J Hill; Leigh A Stoddart
Journal:  Br J Pharmacol       Date:  2020-02-06       Impact factor: 8.739

6.  Membrane Lipids Are an Integral Part of Transmembrane Allosteric Sites in GPCRs: A Case Study of Cannabinoid CB1 Receptor Bound to a Negative Allosteric Modulator, ORG27569, and Analogs.

Authors:  Peter Obi; Senthil Natesan
Journal:  J Med Chem       Date:  2022-09-06       Impact factor: 8.039

7.  Kinetic profiling and functional characterization of 8-phenylxanthine derivatives as A2B adenosine receptor antagonists.

Authors:  Anna Vlachodimou; Henk de Vries; Milena Pasoli; Miranda Goudswaard; Soon-Ai Kim; Yong-Chul Kim; Mirko Scortichini; Melissa Marshall; Joel Linden; Laura H Heitman; Kenneth A Jacobson; Adriaan P IJzerman
Journal:  Biochem Pharmacol       Date:  2022-04-06       Impact factor: 6.100

8.  Engineering Factor Xa Inhibitor with Multiple Platelet-Binding Sites Facilitates its Platelet Targeting.

Authors:  Yuanjun Zhu; Ruyi Li; Yuan Lin; Mengyang Shui; Xiaoyan Liu; Huan Chen; Yinye Wang
Journal:  Sci Rep       Date:  2016-07-19       Impact factor: 4.379

9.  Membrane-Facilitated Receptor Access and Binding Mechanisms of Long-Acting β2-Adrenergic Receptor Agonists.

Authors:  Christopher T Szlenk; Jeevan B Gc; Senthil Natesan
Journal:  Mol Pharmacol       Date:  2021-08-01       Impact factor: 4.054

10.  Structure-Affinity Relationships and Structure-Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists.

Authors:  Lizi Xia; Henk de Vries; Eelke B Lenselink; Julien Louvel; Michael J Waring; Leifeng Cheng; Sara Pahlén; Maria J Petersson; Peter Schell; Roine I Olsson; Laura H Heitman; Robert J Sheppard; Adriaan P IJzerman
Journal:  J Med Chem       Date:  2017-11-21       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.